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Success of product development measured by new product introductions to the market is a key 
performance indicator for business today. Often internal processes are mentioned in relation to 
product development optimization. However, the external environment is also critical for product 
development success. Insights from the alliance and network literature point to benefits such as 
access to knowledge and capabilities, which enable the firm’s innovative processes. In particular, 
effects of network relations are analyzed focusing front-end discovery phases of NPD processes. 
Here, it is observed that small entrepreneurial start up company’s supply knowledge to network 
alliances with well-established and financially strong companies. However, in the later stages of 
development the main influence of external partnerships is described as financial support and 
joining distribution efforts, rather than knowledge sharing as main motivator for engaging in 
cooperative network or alliance efforts. Extending this perspective, not the least the user-driven 
innovation research has emphasized the important input to new product development provided 
by users. While integration with this ‘down-stream’ partner can provide valuable information for 
the early stages of product development – even triggering substantial innovation – forming 
relations to customers and users can in many industries have the character of not only a 
knowledge input, but also knowledge sharing through a community of practice of professional 
peers. Such network formations between firms and its customer base may then also contribute to 
later stage product development tasks.  
It is the main proposition of this research that characteristics of the network between the focal 
firm and its customer or market partners will impact the performance of later stage product 
development tasks. While networks can be characterized by a number of measures like breadth, 
density, and structural characteristics, more recent developments in network and alliance 
management need to be specifically accounted for. In particular, it is observed that companies 
today often integrate a ‘mediator partner’, brokering the external relations, including connection 
to customers.  
This study will explore this field of research focusing on the pharmaceutical industry. As such, 
this study addresses a gap in the literature concerning the relation to hospital partners influencing 
the later stages of development. Hospitals and medical centers are the main costumers of new 
drugs, and they also form a collaborative partnership in the product development phases of 
clinical trials, where new products are tested before obtaining market approval. Hospitals and 
medical centers have unique knowledge of the therapeutic area of the new products, and relations 
to a large number of patients, which is essential for clinical trial recruitment.  
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The relations between hospitals and pharmaceutical companies have however been changing 
over the last years, as brokering agents are becoming an increasingly important part of the 
system, the so-called Contract Research Organizations (CROs). Therefore, the pharmaceutical 
industry is an interesting case for exploring the influence of multilevel network relation’s 
influence on product approvals.  
In this paper, the connection between network alliances and development success is studied 
through a systemic literature analysis. We review the network and alliance management 
literature and combine it with research from the industrial marketing field focusing on down-
stream cooperation management to develop research propositions. To add richness to our 
conceptual model, we further include qualitative case studies supporting grounded theory 
building.  
 
In sum, this paper contributes to the literature by the following: (1) We develop a systematic 
overview over network characteristics shown to have impact for new product development. (2) 
We discuss how recent developments of management practice, with respect to integrating broker 
functions in network and alliance management, alter the relationships between network 
characteristics and new product development and performance, and (3) We focus ‘down-stream 
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INTRODUCTION 
The perception that a company’s in-house resources alone can develop unique new products is 
changing. Today companies are pursuing resources in their external network to optimize the 
knowledge and expertise necessary for the development of unique products to the market 
(Zaheer and Bell 2005). It is recognized that a firms external network influence firm 
performance positively by stimulating innovation and learning (Ahuja 2000; Gulati ét al. 2000; 
Burt 1992). Here strategies pursuing alliances have been prevalent in new product development, 
as a method to access complimentary assets and through that optimize processes of product 
development (Cassiman and Veugelers 2006; Knudsen and Nielsen 2008). However, other actors 
in the firms’ external network are increasingly emphasized as a key resource for input to new 
product development. Customers and users of potential new products represents a unique 
opportunity to utilize know-how and need-dynamics, which can stimulate in-house knowledge 
and learning in product development (von Hippel 1988). The utilization of user insights is 
especially interesting in the perspective of high-tech industries, as the market often constitutes 
professionals with unique expertise in the product area, and therefore are an opportunity for 
companies to tap into cutting edge knowledge.  
Often network resources and especially resources related to knowledge exchange and input have 
been related to up-stream innovation processes (Powell 1996). However, in the down-stream 
innovation processes external network resources may greatly benefit the firm and is therefore an 
important factor to consider in late stage development.  
With an increase in utilization of external resources a new type of player has entered the network 
structure. Broker agents have been integrated in the relationship between partners in 
development networks, which alter the existing processes and are therefore an issue to consider 
in the management of external resources with the goal of optimizing development capabilities 
(Howells 2006; Hargadon and Sutton 1997; Bessant and Rush 1995).  
To understand the influence of external network relations on product development success this 
paper focuses on the pharmaceutical industry. Pharmaceutical and biopharmaceutical drug 
development is an example of an industry increasingly opening up the otherwise closed 
development process and entering a more external approach to product development. In order to 
optimize productivity an increase of alliances and licensing partnerships have been evident over 
the last years. Further, the pharmaceutical industry is an interesting case of down-stream 
partnerships, as future customers are directly integrated in the processes of product development, 
as all new products are to be tested on patients before market entry. New product prospects 
undergo extensive testing phases following strict clinical trials, which are conducted by medical 
physician and personal at private clinics, health centers, and hospitals.  
The testing process is initiated after intensive laboratory research and animal testing. Successful 
compounds in the discovery and initial development stages enter the next stage of development, 
the clinical trial phases, where the new products are tested on humans. These clinical trials 
comprise of three primary stages, phase I – III. The trials intensify with respect to the number of 
participants throughout the three phases. In phase I there are usually less than 100 participants 
(i.e. individuals involved in testing the new pharmaceutical product) where safety is the prime 
goal. Phase II requires 100 – 300 participants, and here efficacy and determination of exact 
dosage is the main aim.  Phase III requires 1,000 or more participants to be included in the trials, 
where the new products longer term effects are compared to an equivalent benchmark product 
(Hathaway ét al. 2009; US Food and Drug Administration FDA). As patients are a main factor in 

the late stages of clinical trials the industry is highly dependent on medical partners, who have 
access to patients, and the expertise in the therapeutic area of the new drug. 
The clinical trial phases have on average a duration of 8 years and cost of succeeding through all 
clinical phase including expenses for failed entities is estimated to an average of $ 800 million, 
which amount to around 50 % of the overall R&D expenses of developing a new drug (DiMasi, 
2001; Struck, 1994; DiMasi and Grabowski, 2007; European Federation of Pharmaceutical 




FIGURE 1: New product development process of the pharmaceutical industry 
The clinical trials are a substantial element in the NPD of the industry due to the extensive time 
and costs spend on theses stages, and are a continuing challenge to the industry’s productivity 
(The Pharmaceutical Research and Manufacturers of America, PhRMA; FDA). Therefore, the 
industry has increasingly been focused on opportunities in the external environment to find 
models for optimizing the complex and resource intensive process of product testing. One of 
these is the integration of broker agents, referred to in the industry as Contract Research 
Organizations (CRO), who undertake tasks previous hold in-house in the industry. The product 
development process will be presented more in detail throughout the progress of the paper.  
METHOD 
The purpose of this paper is to study the influence of firm’s external network relations in down-
stream development processes, and discuss the possibilities in high technology industries to tap 
into unique knowledge amongst external relations such as customers and users. We do this by 
exploring previous literature on alliance and network management literature and combine it with 
the field of industrial product development focusing on down-stream processes. Further, the 
presented structure of network partners in product development are challenged by literature on 
broker function, and this stream of literature will be applied to discuss how this changes existing 
dynamics. The literature review will therefore study the role of down-stream network resources 
in product development by combining perspectives from different fields. First, perspectives from 
alliance and network theory will be presented in relation to down-stream processes. Second, 
users as a network resource in product development are presented, including perspectives on 
communities of practice and the influence of professional network relations. Third, the presented 
network dynamics are challenged by the introduction of broker agent perspectives.  
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To add richness to the conceptual framework discussed in the paper, and to challenge the 
theoretical perspectives, the paper will draw on examples from the pharmaceutical industry. In 
particular, examples from drug development processes are presented throughout the paper, to 
provide an empirical approach fit for extending the conceptual model of later stage new product 
development cooperation. The conceptual model presented in the paper will then lead to a 
discussion of managerial challenges in down-stream innovation and direction for further research 
in this field.  
 
 
DOWN-STREAM NETWORK CHARACTERISTICS 
Almost 25 years ago Håkansson and Snehota (1989) declared that ‘no business is an island’, 
presenting an external perspective on strategic management. The perception of a firm with clear 
boundaries defining firm resources, as presented by the transaction cost economic theory, was 
thereby challenged (Coase 1937; Williamson 1975). Firm’s capabilities are thereby not limited to 
in-house resources, but external network relations are perceived as assets, which can be utilized 
and contribute to firm performance (Gulati 1998; Zaheer and Bell 2005). This is especially the 
case in the perspective of product development processes, as it is today widely recognize. Firms’ 
external resources are accepted as an integral element in the development of unique products for 
the market. Firms cannot rely solely on their internal capabilities when developing new products, 
but also needs to pool external resources (Gold 1987; Zaheer and Bell 2005).  
A company’s external networks of stakeholders are therefore of vast importance for the 
processes of product development. This is often observed in the up-stream processes of product 
development, where companies may enter alliances or create licensing agreements in order to tap 
into complimentary capabilities needed in the research and development of new products (Powell, 
1996; Reid and de Brentani, 2004). This can for example be observed in high technology 
markets when products are discovered and initially developed in one, often smaller 
entrepreneurial, company, and being further developed in partnerships with another company 
with complementary capabilities for late stage development tasks. Development resources are 
thereby acquired in alliances or licensing structures, where financially strong companies tap into 
new and promising product ideas from smaller companies in the initial discovery phases (Bower 
1993; Teece 2000; Pisano 1997).  
This trend in new product development is especially prevalent in development of new 
pharmaceutical and biopharmaceutical products (Deeds and Hill 1996; Bower 1993). New 
entities are often discovered and initially developed in one company, and then in the later stages 
of development licensed or an alliance is entered with another, often financially stronger 
company on the market (Pisano 1997; McCutchen and Swamidass, 2004; Arora ét al. 2000; 
Pisano 2006). From the initial discovery phases in the pharmaceutical industry only one in five 
thousand succeeds and is therefore considered promising enough to pass on to the clinical trial 
phases (European Federation of Pharmaceutical Industries and Associations Efpia - The 
pharmaceutical industry in figures. 2009 update). As the success rate of new products through 
development is distinctively low in this industry, pharmaceutical companies continuously need 
new promising entities in their product pipeline  (Grabowski and Kyle 2007, McCutchen ét al. 
2008). A strategy of entering alliances with companies with promising entities or licensing an 
entity after the initial discovery phases has become a popular strategy in the industry to meet the 
challenge of optimizing the level of promising new entities in the product pipeline (Pisano 1997, 
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Bower 1993). The strategy of pooling network resources in the discovery phases of product 
development illustrates how companies are utilizing external resources and not only developing 
products from internal capabilities in the fuzzy front end.  
However, external resources are not only important in up-stream processes. The same examples 
of alliances between small companies with new discoveries and larger financially strong 
companies illustrate that in the later stages of development financial capabilities are of vast 
importance in the pharmaceutical industry. The trial phases in drug development represents the 
dominant investment in developing new products, as it requires extensive financial capabilities to 
conduct the time consuming and extensive later stages of development. This is further 
emphasized by the high risk of failure in the later phases, as the probability of promising new 
entities from the discovery phases to succeed the three clinical trial phases are only one in five 
(DiMasi, 2001; DiMasi and Grabowski, 2007). This high level of uncertainty in this very late 
stage of development makes financial strength an essential asset in order to pursue these down-
stream activities. Further, studies on clinical trial experience have shown that companies, who 
have developed know-how in conducting and managing these phase of development where many 
regulatory issues are challenging, have a higher success rate  (Danzon ét al. 2005). Therefore, 
companies with financial strength and experience in the regulatory requirements in these trial 
phases are a valuable resource in down-stream innovation and an asset of necessity for smaller 
companies with less financial strength and experience in down-stream processes.  
Studies conducted about network resources in pharmaceutical product development focus mainly 
on these industrial networks where a company supplies up-stream resources, primarily focused 
on knowledge input in relation to new entities, and down-stream resources primarily focused on 
financial capabilities and experience in regulatory processes from partner companies. However, 
this focus on industrial partners neglects other important actors of influence to the development 
process. Utilizing user knowledge can be beneficial for the new product development processes, 
as users have unique insight into product use and user needs and can therefore supply input in the 
creation and development of new products. In the next part of the paper the role of the user in 
product development processes will be explored further. The terms ‘users’ and ‘customers’ are 
applied interchangeable in this paper, however a distinction and more in depth analysis on the 
difference is a relevant topic for further research, but outside the scope of this paper.  
 
 
Influence of users in product development 
Pooling resources from other companies are not the only external source of input that firms 
utilize in product development. Von Hippel (1988) expanded the perspective on sources of 
innovation by presenting users as a main resource for new product developments. He discusses 
how the perspective on users has changed from actors representing market needs, which industry 
could try to identify and fulfill, to a perspective on users as having an actual influence on the 
development process and the final products ready for the market (Von Hippel 2005). Users are 
seen as an increasing source of input in new product development, contributing to firm 
performance (von Hippel 2005; Shah 2000; Rothwell 1994). Some users are especially 
emphasized and defined as ‘lead users’ with unique knowledge about the future end-user market 
of a new product, as well as specific knowledge on the product area (von Hippel 1986; Urban 
and von Hippel 1988; Shah 2000). These lead users may have cutting edge knowledge of the 
product area (Rothwell 1994) through their professional expertise and thereby represent 
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knowledge of excellence (Shaw 1988), and may even form communities where they share 
knowledge and learn from each other (Franke and Shah 2002).  
The user influence on the development process is often observed in the earlier stages of 
development where new ideas are discovered. The user-driven perspective of innovation presents 
the user as a resource with unique need related knowledge and therefore as an important partner 
in the discovery of new product ideas. Von Hippel (1988) emphasizes that often the user even 
discovers the actual new idea, develops the prototype and hereafter engages with industry for the 
late stages of development. The users thereby fulfill their own needs by inventing new products 
and are a major influence on the pipeline in up-stream innovation. The motive behind this 
activity by users is driven by their possible gain from the new product by fulfilling a need they 
define (von Hippel 1988). 
Even though the pharmaceutical industry is based on a very high-technology discovery process, 
indications of up-stream user developments can be observed. Physicians or medical scientists at 
university hospitals sometimes develop new products, as these actors have expert knowledge on 
their medical area and also have direct interaction with patients and therefore patient needs. Later 
in the process these actors or organizations will then often form alliances with private industry in 
the expensive down-stream processes (Bower 1993).  
Besides being an asset in up-stream innovation, users and customers are also a relevant network 
resource in down-stream innovation processes. Users may be integrated in the later stages of 
development, when new products are being tested before market launch. Extant literature on user 
roles in down-stream processes presents the user in relation to prototype development (Shaw 
1988) and prototype testing in the late stages of development often conducted for marketing 
purposes (Thomke and von Hippel, 2002; Cooper 2001). However, there is limited knowledge on 
the character and scope of user influences in these late stages of development. We therefore turn 




The role of users in down-stream processes in drug development 
The pharmaceutical industry is an interesting example of how users and customers are 
sometimes highly integrated in the later development processes of new products. Drug 
development introduces specific examples of influence from users in down-stream innovation 
processes, and such examples can thereby contribute with perspectives on user input 
characteristics. In extant literature on user influence in down-stream development such as 
prototype development and testing processes it is only to a limited degree explained how users 
actually influence the processes and the scope of this influence (Thomke and von Hippel, 2002; 
Cooper 2001). There is limited literature exploring the actual input from users in the down-
stream process and how this is shared and utilized by the company.  
In the pharmaceutical industry an important interaction between in-house staff from companies 
and users from medical sites during the clinical trial phases occurs. Physicians both in private 
clinics and in large medical sites such a hospitals are central users of products on the market 
through their direct relation to patients and their treatment methods. Also physicians have a more 
direct role in pharmaceutical product development, as they are integrated in the testing of new 
products, which may give access to the market. The pharmaceutical industry is an unique 
example of product testing processes, as the new products undergo extensive clinical research 
processes, where it is required to collaborate with users as they can conduct the actual patient 
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trials and supply the necessary information for the regulatory authorities. The physician’s link to 
patients is therefore a valuable asset for the pharmaceutical industry, as well as physician’s 
expertise in the therapeutic area, which is needed to conduct and observe trials. The 
pharmaceutical industry therefore partner-up with medical sites in order to conduct the clinical 
trials, where the new products are tested for safety and efficacy to acquire approval for market 
launch (Getz and Zuckerman 2010). Physicians at medical clinics and hospitals collaborate with 
a company’s in-house clinical staff when trials of the new products are conducted. Companies 
develop trial protocols as well as manuals for product use, which sites apply in the clinical trials. 
Feedback from the sites on safety and efficacy of the new products are then reported back to the 
company and entails the application to the regulatory authorities for gaining approval of the new 
product to the market (Hathaway ét al. 2009). Physicians are thereby integrated in the 
development of new products before market launch, thus presenting an example of how users in 
some industries are a central player in the down-stream processes.  
Previous studies on pharmaceutical product development have pointed to the importance of the 
relationships to these users for the outcome of trials and market introduction. Danzon ét al. 
(2005) have studied the impact of experience in the trial processes on trial outcome. They found 
a positive correlation between trial success and experience in the trial processes such as 
designing and managing trials, and continuous relationships to clinical sites and therefore 
physicians. This study is interesting, as it illustrate that the process of user integration in the 
testing process not only is a matter of standardized feedback, but that the actual relationship 
between users and industry in the down-stream development process are important, and that the 
network created over time may influence trial outcome. Another example of the influence of 
users in the trial phases has in previous studies been illustrated in relation to market introduction. 
Glass (2004) has studied the influence of the relationship to physicians in relation to the adoption 
of the new products to the market. These studies point to the importance of physician-industry 
relations, as physicians participating in clinical trials are more likely to prescribe the new product 
after market launch. Sismondo (2008) discuss this phenomenon and mentions how clinical trials 
familiarize physicians with the new products, which may impact their behavior in relation to 
prescribing the new product and therefore influence the performance of the new product on the 
market.  
The role of users in drug development illustrate that ongoing collaboration between user and in-
house staff may influence success of clinical trials, as well as adoption of products after market 
entry. Professional interaction is a central issue describing this interaction as both users and the 
in-house staff is knowledgeable within the field. Users are highly qualified professionals and in-
house representatives are not only marketing personal, but clinical staff with specific product 
knowledge. The testing process is therefore not only a marketing process but an exchange of 
specific knowledge determining the new entities possibilities to obtain market approval. Next we 
will therefore draw on perspectives on professional network interaction between in-house staff 
and external resources in order to explore the possibilities of users in down-stream development.  
 
 
Professional network resources  
Von Hippel (1988) introduces the term ‘informal knowledge exchange’ in relation to utilizing 
knowledge from professional peers at rival companies. The perspective of information 
knowledge exchange is also presented in perspectives of coopetition, where competing 
companies collaborate in often informal relations (Bengtsson and Kock 2000; Dyer and Singh 
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1998). This perspective introduces insights into the possible influence of external actors as in-
house personal may engage in both formal and informal professional interaction to gain new 
knowledge and exchange professional experiences. In high-technology markets the users are in 
many cases professionals with unique knowledge not only about user behavior, but also about 
the field of the specific industry. Therefore user influence in the product development process 
may not only have character user-need input from user to producer, but the relation can better be 
characterized as a knowledge exchange among professionals, as industry staff may be from the 
same professional field as the users. According to Wenger (2000) there exist different social 
communities of practice where unique knowledge is defined over time and this knowledge 
becomes social competences within the community. Such communities are often groups of 
individuals with competencies within the same profession or area, which over time evolves joint 
understanding. These social communities together with personal competencies make it possible 
for new knowledge and innovation to emerge (Wenger 1998): “In these learning systems, 
organizations find the talents they need, new ideas, technological developments, best practices, 
and learning partners” (Wenger, 1998: 244).  
Communities of practice are most often applied to define professional network relations between 
companies and for example universities or other knowledge centers central for high-technology 
product development (Lynn ét al. 1996). But in high-technology industries products are often 
disseminated to professionals within the field. The relations to customers and users can in many 
industries have the character of not only a knowledge input but also knowledge sharing through a 
community of practice of equal professionals with knowledge of the product area (Wenger 1998).  
This is also the case in the pharmaceutical industry, where the central users of new products are 
physicians at medial centers through their relation to patients. The relationship between the in-
house clinical staff and the clinical investigators at hospitals has similarities to Wenger (1998) 
communities of practice. In drug development professional communities of individuals are 
developed over time, which generate optimal opportunities of knowledge sharing. Direct clinical 
participation represents a way for sponsor companies to develop strong relationships with 
practicing physicians, not only by communicating with potential prescribers, but by learning 
directly from them as well (Glass 2004 in Pharmaceutical Executive). As the study from Glass 
(2004) illustrate, the down-stream network with physicians has a professional impact on the 
development process, as industry clinical staff and physicians at medical sites interact and 
exchange knowledge. This is also mentioned by Danzon ét al. (2005) in relation to trial 
experience and the impact of relations to physicians for trial success. Learning-by-doing may 
produce general and category-specific skills in designing and managing trials, and improve 
relationships with clinicians and regulators, thereby contributing to trial success rates (Danzon 
ét al. 2005, 319). This corresponds with the perspectives mentioned by Wenger (2000) as the 
communities of practice generating knowledge exchanged are generated over time. The 
continuous relationship between companies and the physicians developed over time thereby 
creates conditions, which may generate what von Hippel (1988) identified as informal 
knowledge exchange, and be a unique source of input to the late stages of development in the 
pharmaceutical industry. Especially as the development process in drug development are so 
extensive and conducted over so many years, potential input from clinical sites may influence 
later stages of development and optimize the process and later commercialization.  
However, the structure where companies interact directly with physicians in the drug 
development have seen profound changes over the last years, changes that may challenge the 
knowledge flow from physicians to the pharmaceutical industry in product development.  
 
The expenses of clinical trials are continuingly increasing in the pharmaceutical industry even 
though more products are not entering the market (Kaitin 2010). There is therefore a common 
understanding in the industry that the extensive time-consuming and costly development process 
needs to be more effective. These motives have made pharmaceutical companies outsource 
previous in-house competences, such as site selection and data management, which are both 
closely connected to the relationship to trials, to a contract research organization (CRO) (Getz 
and Zuckerman 2008). It has been recognized that the integration of a CRO may generate 
savings on cost and time  (Getz 2007; Kaitin 2010) as these organizations are specialized in the 
down-stream task of clinical trial management.  
 
FIGURE 2: Main external resources in the drug development process 
The majority of extant literature on increasing influence of CRO partners in pharmaceutical 
product development focuses in the advantages and challenges from an outsourcing perspective 
(Metha and Peters 2007; Getz and Zuckerman 2008). The increasing use of CRO services is 
observed from an outsourcing perspective, as services previously held in-house in the 
pharmaceutical industry are continuously being outsourced to a second party (Getz and 
Zuckerman 2008). Outsourcing of central tasks and resources in the development process are 
also recognized by Howells (1999) and Ringe (1992), who defines the term of Contract Research 
and Technology Organizations (CRTO) as …work of an innovatory nature undertaken by one 
party on behalf of another under conditions laid out in a contract agreed formally beforehand 
(Ringe 1992). Applying an outsourcing strategy in product development enables companies to 
focus on their core capabilities by contracting out tasks, which are not considered to be central to 
the company’s core competences (Howells 1999). In the pharmaceutical industry this has caused 
an increase in the use of CRO functions in relation to late stages of product development, when 
products are tested in clinical trials. The use of outsourcing in the late stage of drug development 
now often included CROs managing the direct relations to trial sites as companies outsource 
clinical trial processes in a full service partnership (FSP) (Getz and Zuckerman 2008; 
Bodenheimer 2000). The CRO thereby mediates the relationship between two key actors in drug 
development and it is therefore relevant to take on a brokerage perspective. Tasks of product 
development are not only outsourced to a second party, but the CROs are increasingly becoming 
a third party agent between network relations in the clinical trials. The next part of the paper will 
therefore turn to the perspective of broker agents and how this expansion of the network 
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With a growing external perspective on new product development a company’s external network 
relations are naturally of great importance. This have brought by new types of organizations 
assisting companies in their endeavors reaching out to external resources in their development 
processes. Companies mediating relationships to external stakeholders have entered the product 
development framework (Howells 2006; Hargadon and Sutton 1997; Bessant and Rush 1995). 
The role of this third party partner functioning between existing organizations have been defined 
in different terms, such as intermediaries (Shohet and Prevezen 1996; Howells 2006), 
consultants bridging a gap (Bessant and Rush 1995), superstructure (Lynn ét al. 1996) and 
brokers (Hargadon and Sutton 1997; Could and Fernandez 1989).  
These mediators of relations in companies’ external environment have thereby also been referred 
to in relation to different functions in the innovation process. The perspectives of mediators are 
often presented as being the role of bridging firms and optimizing relations to external resources 
and partners that otherwise may be difficult for firms to tap into (Bessant and Rush 1995; 
Hargadon and Sutton 1997). Lynn´ (1996) presents a perspective on innovation communities that 
emphasizes a superstructure of organizations with the role of generating flow of knowledge in a 
community of technical related organizations. The superstructure is thereby the generator of 
optimizing knowledge flow or creating conditions for knowledge flow, which may otherwise be 
limited. The function of brokerage thereby refers to a position in a social network where an actor 
is connecting other actors in the system, which is not directly tied to each other (Burt 1992; 
Marsden 1983; Could and Fernandez 1989). Broker function gain a powerful role through its 
position connecting otherwise not connected ties and thereby obtaining optimal position in a 
network in relation to information flow, which may influence performance of that player (Burt 
1992). Broker agents are therefore filling a structural hole, by being the direct link between two 
actors, who are only linked through indirect ties, and thereby generating increased influence in 
the system (Burt 1992). The distinction of direct and indirect ties is further discussed by Ahuja 
(2000) in relation to learning and knowledge input, as it is suggested that both direct and indirect 
ties can influence innovation processes, but indirect ties is dependent on the level of direct ties. 
The position of an actor in relation to other actors in a social network are the key factor 
influencing performance, and the structure of actors are therefore emphasized more than the 
individual attributes of these actors (Burt 1992).  
Could and Fernandez (1989) criticizes social network perspectives on broker functions (Burt 
1976; Galaskiewicz and Krohn 1984) for merely presenting the position of the broker as 
important and excluding the aim of the brokerage pattern. Could and Fernandez (1989) present 
five different roles of the broker functions; local broker/coordinator, cosmopolitan/itinerant, gate 
keeper, representative and liaison. This perspective discuss the position of the broker in relation 
to the partners whom the broker mediates, and present different relations and thereby roles of the 
broker. The broker may belong to the same subgroup as one of the other actors, or none of them, 
and thereby have a different role in relation to this position.  
Often intermediary functions are mentioned in relation to up-stream innovation functions, where 
these partners bridge relations to front-end resources. Intermediaries are found in relation to the 
linkage of public institutions such as universities, to external and often private organizations 
 
relevant for licensing a new technology or otherwise utilize an idea discovered in a university 
environment (Shohet and Prevezer 1996). Further, ideas discovered in university environments 
can be supported by an intermediary function in relation to patent applications and trading 
(Shohet and Prevezer 1996). However, as discussed in this paper, external assets are also pursued 
in down-stream processes of innovation, which generate a potential role of mediators. In 
pharmaceutical down-stream processes the integration of contract research organizations is not 
just an issue of outsourcing, but brokerage, as the CROs manages tasks between two actors. 
Further, the example from the pharmaceutical industry illustrates a broker function that mediates 
a relationship between two actors, who previously had direct interaction in the development 
process, as the CRO manages tasks and relations between sponsor companies and medical sites. 
Broker functions in the pharmaceutical product development are therefore not only applied as a 
mean for companies to gain access to new relations and assets, but third party organizations are 
integrated between existing collaborative partners to optimize the down-stream development 
process. The integration of CRO partners in the pharmaceutical industry thereby illustrates how 
previous direct ties are enforced to become indirect ties, and thereby expands on previous 




  FIGURE 3: Direct site-industry relations.      FIGURE 4: CRO as intermediary agent 
 
 
CROs have entered drug development focusing on the late stages of development, where new 
drug entities enter the clinical trial phases. In the late trial phases CROs are positioned as an 
organization optimizing trial management such as data management and patient and site 
recruitment. The task portfolios of CROs have increased since this type of organizations entered 
drug development about ten years ago. Previous most CRO-sponsor company relationships were 
based on the CRO conducting functional tasks in a transactional relationship, and therefore an 
integration of CRO activities on a single task contract, after the development plan and the 
protocol have been developed. The CRO are therefore integrated to manage some parts of the 
clinical trial tasks and often the sponsor company still has direct connection to the medical sites 
and an active part in the central management task (Getz 2009; Getz and Zuckerman 2008). This 
structure has developed over the years and it can now be observed that in some cases the CRO 
are controlling an increasing part of the clinical trial tasks and therefore becoming a Full Service 
Partner (FLS) supervising the majority of tasks in the trial phases and the relations to medical 
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sites (Getz 2009). The CROs thereby both function as a mediator between pharmaceutical 
companies and new sites and assume the management of previous company relations.  
Even though some perspectives on brokering in the extant literature discuss the aim of brokerage 
(Gould and Fernandez 1989) research has yet to fully capturing the possible gains and 
consequences of this structure of knowledge flow. Mediator roles can also be observed in 
relation to a change in the structure of existing relations in a company’s network, by integrating a 
third partner mediating existing relationships with the purpose of optimizing processes. The 
pharmaceutical industry is therefore an interesting example of an issue, which is not emphasized 
in extant literature on brokerage, where the third party function is changing existing network 
relations shifting them from direct to indirect ties. The integration of CRO partners thereby 




MANAGERIAL IMPLICATIONS FOR DOWN-STREAM INNOVATION 
In the presented literature on outsourcing in product development it is emphasized that a main 
motivation is a focused strategy on core competences. This however bring by the challenge of 
judging what the company’s core competences are in the product development process (Howells 
1999). It is previous mentioned in this paper, that a capability of large pharmaceutical companies 
in down-stream innovation is their financial capabilities relevant for the high risk phases, but 
also their experience in clinical trials and therefore knowledge on regulatory issues and 
embedded relationships with key actors such as the physicians (Danzon ét al. 2005). When the 
relation to the medical sites are being moved to a third party agent the utilization of knowledge 
from the highly competent user at medical sites may be compromised. The use of CROs to run 
clinical studies can make it more challenging for pharma companies to develop relationships 
with investigators (Glass 2004 in Pharmaceutical Executive). The direct tie between sponsors 
and clinical sites may be jeopardized as the task of trial management are not perceived as a core 
competence and therefore moved to a third party agent. This may further create challenges to the 
absorptive capacity (Cohen and Levinthal 1990) of the sponsor company, as the clinical 
competences previously located in-house, are now located at the CRO. Getz (2007) studied the 
clinical in-house staff head count in the pharmaceutical industry and found a decrease of clinical 
staff, while the number of trials as well as R&D expenses increased. This decrease of in-house 
clinical staff occurred in a period, where the use of CRO activities highly increased.  
It can be argued, that the absorptive capacity decrease, as the in-house specialists incorporated in 
the language of medical partners are being relocated to a third party. The interference of CROs 
challenges the opportunity to knowledge about the new products to be absorbed in the sponsor 
companies, as they are no longer directly connected to the trial sites, and as the CRO partners 
may not be as knowledgeable about the product as the in-house specialist working with the 
product for years. CROs often have multiple contracts in the industry simultaneously and are 
naturally not as integrated in the knowledge about new products build over many years of 
research and development as the in-house clinical staff. The absorptive capacity in CROs may 
therefore not be as profound as the sponsor company and so challenges the opportunities for 
absorbing knowledge and learning’s by the physician partners, and further transferring this 
knowledge on to the pharmaceutical company. The flow of unique knowledge obtained in the 
clinical trial phases may therefore be compromised in the new structures of drug development. 
There is a gap in existing literature on this area. There are no studies on the pharmaceutical 
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industry focusing on this issue of drug development. The pharmaceutical industry is an example 
of an industry that has entered into a more network-oriented strategy in product development. 
However, it is also an example of an industry that may not fully be exploring the possibilities 
that exists in the unique relationship to down-stream external stakeholders of the NPD process. 
Late stage network partners are primarily perceived as providers of a necessary service in the 
testing of new products, who can supply concrete and pre-defined information of the clinical 
trials. However, these network partners, the medical centers, are highly qualified knowledge 
workers with in depth knowledge of the new product and the use of this. Knowledge, which 
exceeds the predefined formats and reporting systems, may not be discovered and therefore not 
explored by the industry in the following trials and market launch. This knowledge may often be 
characterized as tacit and this therefore needs to be considered in initiatives for tapping into this 
unique knowledge of the new products.  
 
PROPOSITION 1 
Broker agents have proven to improve drug development by optimizing time and costs of clinical 
research. However, these intermediary agents compromise valuable relations to network 
partners and therefore the knowledge flow between company and professional customers with 
unique knowledge in the product are. 
 
Managerial implications for the down-stream product development processes need to be further 
explored and developed in order to capture the full potential of down-stream input from network 
resources. This requires ability to identify source of knowledge and how to tap into this 
knowledge and utilize it in the organization.  
The example from the pharmaceutical industry illustrates a potential for down-stream input from 
users, which may not have been explored fully due to traditional perspectives on how network 
resources are utilized in down-stream NPD. Further, the increasing role of the CRO mediating 
the relation between users and company in late stage development imply that the importance of 




Focus on external resources in late stage development requires management structures to 
capture the opportunities that may exist in individual industry product development processes. 
Further, these managerial tools should included aspects of the integration of broker functions 
and how these should be managed in order to optimize their potential and minimize 
consequences in relation to central external relations.  
 
The propositions developed on the grounds of this paper will be further explored in an in-depth 
study of the knowledge possibilities at clinical sites in the pharmaceutical industry and an 
analysis of the initiatives engaged to tap into this knowledge. A study on the challenges to 
knowledge flow in down-stream product development in the pharmaceutical industry brought by 
an intermediary agent can generate knowledge about the industry, but also contribute to a gap in 
extant literature on down-stream network resources and the role of broker agents in late stage 
product development.  
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CONCLUDING REMARKS 
This paper has explored the possibilities in down-stream network relations with emphasis on the 
role of users in late stage development. Examples of user inclusion in the pharmaceutical 
industry have illustrated that this central actor should not only be discussed in relation to 
knowledge input and resources in up-stream of innovation, but that users can be a key resource 
in down-stream processes. Further, the role of broker agents in down-stream networks have been 
discussed in relation to the changes this may create for the structure and relationship of the 
involved actors.  
The role of users in down-stream innovation needs to be further explored, in order to understand 
the full influence of this actor and how optimal management tools can be integrated to utilize this 
potential. The pharmaceutical industry presents an interesting case, as it has been determined that 
the relation between industry and users are of great importance. However, further understanding 
of the actual character of this influence is needed as well as further possibilities of user influence 
not yet explored. A study on user influence in down-stream development can therefore both meet 
a gap in the literature on down-stream network influence in product development and contribute 
with further understanding of the role of broker agents in the network structure in late stage 
development. 
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